The EPO issued European Patent EP4289467A2 to ViaCyte, Inc. on March 25, 2026, for instruments used with implantable encapsulation devices. The patent covers medical instruments designed for implanting and managing encapsulated therapeutic cells, with IPC classifications spanning prosthetics (A61F), surgical devices (A61B), implantable materials (A61L), and drug delivery systems (A61K, A61M). The patent designates all EU contracting states including DE, FR, IT, ES, NL, BE, AT, CH, and others.

Patent holders, licensees, and companies developing similar cell therapy delivery systems should verify freedom to operate in European markets. Competitors in the implantable encapsulation space should assess whether their technologies fall within the scope of this patent. This is a routine patent publication creating intellectual property rights rather than regulatory compliance obligations.